ANI Pharmaceuticals
ANIP
123 hedge funds and large institutions have $285M invested in ANI Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.
49% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $9.79M
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
2% more funds holding
Funds holding: 121 → 123 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.66% less ownership
Funds ownership: 60.24% → 54.58% (-5.7%)
35% less capital inflows, than outflows
Capital inflows: $47.3M | Capital outflows: $72.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
+$7.91M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.86M |
| 3 |
First Manhattan
New York
|
+$6.62M |
| 4 |
Lazard Asset Management
New York
|
+$2.64M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$9.81M |
| 3 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$9.45M |
| 4 |
Oberweis Asset Management
Lisle,
Illinois
|
-$6.25M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$4.73M |
ANIP Hedge Fund Activity: Q4 2015 in Review
123 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2015, worth a combined $285M — up 3.5% from $276M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ANIP positions and 21 closed out — a net gain of 3 holders — while 41 added to existing stakes and 36 trimmed.
The largest buyer was Senzar Asset Management, adding an estimated $7.91M. The largest seller was State Street, cutting an estimated $10.7M.
- 123 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2015, up from 121 in Q3 2015.
- Funds reported $285M of ANI Pharmaceuticals stock for Q4 2015, up 3.5% quarter-over-quarter.
- 24 funds opened new ANI Pharmaceuticals positions in Q4 2015 and 21 closed out, a net change of +3 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2015 was Senzar Asset Management, an estimated $7.91M added.
- The largest ANI Pharmaceuticals seller in Q4 2015 was State Street, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2015.